Hypertension

Primary Care - Clinics in Office Practice

Volumn 40, Issue 1, 2013, Pages 179-194

  Winter, Katherine H ^a   Tuttle, Laura A ^a   Viera, Anthony J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Antihypertensive therapy; Blood pressure; Calcium channel blockers; Diabetes; Diuretics; Hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; SPIRONOLACTONE; TERAZOSIN;

AFRICAN AMERICAN; AGE DISTRIBUTION; ALCOHOL ABSTINENCE; AORTA COARCTATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COUGHING; CUSHING DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; FAMILY HISTORY; FATIGUE; FIBROMUSCULAR DYSPLASIA; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMOBILIZATION; KIDNEY ARTERY STENOSIS; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MICROALBUMINURIA; MORBIDITY; MORTALITY; MYALGIA; OBESITY; ORGAN INJURY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; REBOUND HYPERTENSION; REFLEX TACHYCARDIA; RESISTANT HYPERTENSION; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SLEEP DISORDERED BREATHING; SMOKING; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TARGET ORGAN DAMAGE; WEIGHT REDUCTION;

AFRICAN AMERICANS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNELS; COMORBIDITY; DIABETES MELLITUS; DIURETICS; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; LIFE STYLE; PREVALENCE;

EID: 84873587966     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2012.11.008     Document Type: Review

References (61)

1. Centers for Disease Control (CDC) Vital signs: prevalence, treatment, and control of hypertension - United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep 2011, 60(4):103-108.
2. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
3. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
4. Singh V. Review: ACE-Is or ARBs reduce adverse CV outcomes regardless of baseline systolic blood pressure. Ann Intern Med 2012, 157(2):JC1-JC8.
5. U.S.Preventive Services Task Force Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2007, 147:783-786. AHRQ Publication No. 08-05105-EF-2, December 2007.
6. Forrest B., Viera A.J. Hypertension. Essentials of family medicine 2011, 125-134. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia. 6th edition. P.D. Sloane, L.M. Slatt, M.H. Ebell (Eds.).
7. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age and older. N Engl J Med 2008, 358:1887-1898.
8. Khan N., Hemmelgarn B., Padwal R., et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 2007, 23:539-550.
9. Sacks F.M., Svetkey L.P., Volmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001, 135:1019-1028.
10. Reid C.M., Maher T., Jennings G.L. Substituting lifestyle management for pharmacological control of blood pressure: a pilot study in Australian general practice. Blood Press 2000, 9:267-274.
11. Qureshi A.I., Sapkota B.L. Blood pressure reduction in secondary stroke prevention. Continuum (Minneapolis Minn) 2011, 17(6 2ndary Stroke Prevention):1233-1241.
12. Goldstein L., Bushnell C., Adams R., et al. Guidelines for the primary prevention of stroke. Stroke 2011, 42:517-584.
13. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
14. Sierra C. Cerebral small vessel disease, cognitive impairment and vascular dementia. Panminerva Med 2012, 54:179-188.
15. Grosso A., Veglio F., Porta M., et al. Hypertensive retinopathy revisited: some answers, more questions. Br J Ophthalmol 2005, 89:1646-1654.
16. Omura M., Saito J., Yamaguchi K., et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004, 27:193-202.
17. U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Revised May 2005. Available at: Accessed August 27, 2012. http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf.
18. Viera A.J., Neutze D.M. Secondary hypertension: an age-based approach. Am Fam Physician 2010, 82:1471-1478.
19. Eklof H., Ahlstrom H., Magnusson A., et al. A prospective comparison of duplex ultrasonagraphy, captopril renography, MRA, and CTA in assessing renal artery stenosis. Acta Radiol 2006, 47:764-774.
20. Nadasdy T., Hebert L.A. Infection-related glomerulonephritis: understanding mechanisms. Semin Nephrol 2011, 31:369-375.
21. Tsai J.D., Huang C.T., Lin P.Y., et al. Screening high-grade vesicoureteral reflux in young infants with a febrile urinary tract infection. Pediatr Nephrol 2012, 27:955-963.
22. Mousa A.Y., Campbell J.E., Stone P.A., et al. Short- and long-term outcomes of percutaneous transluminal angioplasty/stenting of renal fibromuscular dysplasia over a ten-year period. J Vasc Surg 2012, 55:421-427.
23. Olin J.W., Sealove B.A. Diagnosis, management, and future developments of fibromuscular dysplasia. J Vasc Surg 2011, 53:826-836.
24. Hirsch A.T., Jaskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary. Circulation 2006, 113(11):1474-1547.
25. Foy A., Ruggiero N.J., Filippone E.J. Revascularization in renal-artery stenosis. Cardiol Rev 2012, 20:189-193.
26. Wheatley K., Ives N., Gray R., et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009, 361:1953-1962.
27. Klein I., Danzi S. Thyroid disease and the heart. Circulation 2007, 116:1725-1735.
28. Acelajado M.C., Calhoun D.A. Aldosteronism and resistant hypertension. Int J Hypertens 2011, 2011:837817.
29. Fogari R., Preti P., Zoppi A., et al. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007, 30:111-117.
30. Armitage P., Rose G.A. The variability of measurements of casual blood pressure: a laboratory study. Clin Sci 1966, 30:325-335.
31. Pickering T.G., Gerin W., Schwartz A.R. What is the white-coat effect and how should it be measured?. Blood Press Monit 2002, 7:293-300.
32. Viera A.J., Hinderliter A.L., Kshirsagar A.V., et al. Reproducibility of masked hypertension in adults with untreated borderline office blood pressure: comparison of ambulatory and home monitoring. Am J Hypertens 2010, 23:1190-1197.
33. Shimbo D., Pickering T.G., Spruill T.M., et al. Relative utility of home, ambulatory, and office blood pressures in the prediction of end-organ damage. Am J Hypertens 2007, 20:476-482.
34. Verberk W.J., Kroon A.A., Kessels A.G., et al. The optimal scheme of self blood pressure measurement as determined from ambulatory blood pressure recordings. J Hypertens 2006, 24(8):1541-1548.
35. Viera A.J., Cohen L.W., Mitchell C.M., et al. How and why do patients use home blood pressure monitors?. Blood Press Monit 2008, 13(3):133-137.
36. Cappuccio F.P., Kerry S.M., Forbes L., et al. Blood pressure control by home monitoring: meta-analysis of randomized trials. BMJ 2004, 329:145-151.
37. Ohkubo T., Hozawa A., Yamaguchi J., et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-hour blood pressure: the Ohasama study. J Hypertens 2002, 20:2183-2189.
38. Staessen J.A., Thijs L., Fagard R., et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999, 282:539-546.
39. Kario K., Pickering T.G., Umeda Y., et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003, 107:1401-1406.
40. Myers M.G. Automated office blood pressure recorded at one minute intervals. J Hypertens 2011, 29(e-supplement A):e426.
41. Myers M.G., Godwin M., Dawes M., et al. Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. Fam Pract 2012, 29:376-382.
42. Beckett L., Godwin M. The BpTRU automatic blood pressure monitor compared to 24-h ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. BMC Cardiovasc Disord 2005, 5:18.
43. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults, topic page. June 2008. Available at: Accessed December 8, 2012. http://www.uspreventiveservicestaskforce.org/uspstf/uspsdiab.htm.
44. Pignone M., Alberts M.J., Colwell J.A., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. American Diabetes Association; American Heart Association; American College of Cardiology Foundation. J Am Coll Cardiol 2010, 55:2878-2886.
45. Buse J.B., Ginsberg H.N., Bakris G.L., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114-126.
46. ACCORD Study Group, Cushman W.C., Evans G.W., Byington R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
47. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicenter, randomized, double-blind, controlled trial. Lancet 2008, 372:547-553.
48. Triplette M.A., Rossi J.S., Viera A.J., et al. The contribution of hypertension to black-white differences in likelihood of coronary artery disease detected during elective angiography. Am J Hypertens 2011, 24:181-186.
49. Cushman W.C., Davis B.R., Pressel S.L., et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) 2012, 14(1):20-31.
50. National Kidney Foundation Guideline. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002, 39:S1-S246.
51. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863.
52. Wright J.T., Bakris G., Greene T., the African American Study of Kidney Disease and Hypertension (AASK) Study Group, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results of the AASK trial. JAMA 2002, 288:2421-2431.
53. United States Renal Data System USRDS 2007 Annual data report 2007, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda (MD).
54. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
55. Viera A.J., Hinderliter A.L. Evaluation and management of the patient with difficult-to-control or resistant hypertension. Am Fam Physician 2009, 79:863-869.
56. Bangalore S., Kamalakkannan G., Parkar S., et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120:713-719.
57. Egan B.M., Bandyopadhyay D., Shaftman S.R., et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012, 59(6):1124-1131.
58. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352-358.
59. Ernst M.E., Neaton J.D., Grimm R.H., et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension 2011, 58:1001-1007.
60. Dorsch M.P., Gillespie B.W., Erickson S.R., et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011, 57:689-694.
61. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.